Trial Profile
A Study of NanoPac in Non Small Cell Lung Cancer (NSCLC)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Jun 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Jun 2020 According to a NanOlogy media release, FDA allowed IND for nebulized inhalation of NanoPac in Non Small Cell Lung Cancer (NSCLC).
- 14 May 2019 According to a NanOlogy media release, the company is finalizing preclinical work of inhaled NanoPac in preparation for an investigational new drug (IND) submission to the US FDA in mid-2019 to allow for this clinical trial in NSCLC.
- 26 Sep 2018 New trial record